

Iron Horse Diagnostics, Inc. is a privately held molecular diagnostic company focused on the development and commercialization of novel tests to support the diagnosis and management of amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), and other neurological diseases.
Iron Horse has developed and validated assays to measure protein-based signatures of disease. Our first product line will be blood-based and cerebrospinal fluid-based diagnostic tests for ALS. We will also have a biomarker panel to monitor ALS disease progression. Our next product will be a blood-based test for TBI and a biomarker panel to assay neuronal injury using a blood sample. We also expect to use our assays to test the effectiveness of drugs in clinical trials.


The Market
Iron Horse Diagnostics seeks to relieve human suffering for some of the most challenging health disorders. ALS, or Lou Gehrig’s disease, is a devastating disease that is nearly always fatal within 5 years of onset. Traumatic Brain Injury cases have very significant health care costs. Iron Horse will impact these disorders with highly effective diagnostics, enabling early detection.
Learn more on Lou Gehrig's disease (ALS)...
Learn more on Traumatic brain injury (TBI)...
Investing in Iron Horse
Iron Horse is an early stage technology development company with compelling science and strong IP protection. If you are interested in financial projections and investing in Iron Horse, please contact Dr. Bowser.
Learn More...
Contract Laboratory Services
Iron Horse offers contract lab services within our CLIA regulated laboratory for immunologic detection of individual or panels of proteins. We offer services in the following areas:
· Assay Method Development and Validation
· Assay Verification
· Biomarker Testing of Clinical Samples
· Comparative/Competitive Biomarker Evaluation
Iron Horse’s experienced professionals use various assay formats including ELISA and MSD (Meso Scale Discovery), and our testing services ensure timely delivery of high-quality results to our clients.
Learn More...
